Soria JC - Search Results

1

Modifying phase I methodology to facilitate enrolment of molecularly selected patients.

Hollebecque A, Postel-Vinay S, Verweij J, Demetri GD, Flaherty K, Bedard P, Soria JC. Hollebecque A, et al. Among authors: soria jc. Eur J Cancer. 2013 May;49(7):1515-20. doi: 10.1016/j.ejca.2012.12.012. Epub 2013 Jan 16. Eur J Cancer. 2013. PMID: 23333057

2

Use of angiogenesis inhibitors in tumour treatment.

Fayette J, Soria JC, Armand JP. Fayette J, et al. Among authors: soria jc. Eur J Cancer. 2005 May;41(8):1109-16. doi: 10.1016/j.ejca.2005.02.017. Eur J Cancer. 2005. PMID: 15911233 Review.

3

Molecularly targeted agents: their promise as cancer chemopreventive interventions.

Thiery-Vuillemin A, Nguyen T, Pivot X, Spano JP, Dufresnne A, Soria JC. Thiery-Vuillemin A, et al. Among authors: soria jc. Eur J Cancer. 2005 Sep;41(13):2003-15. doi: 10.1016/j.ejca.2005.06.005. Eur J Cancer. 2005. PMID: 16098739 Review.

4

Safety of repeated administrations of ixabepilone given as a 3-hour infusion every other week in combination with irinotecan in patients with advanced malignancies.

Faivre S, Delbaldo C, Boige V, Pautier P, Soria JC, Namouni F, Peck R, Cohen M, Raymond E. Faivre S, et al. Among authors: soria jc. Eur J Cancer. 2008 Mar;44(5):674-82. doi: 10.1016/j.ejca.2008.01.016. Epub 2008 Mar 4. Eur J Cancer. 2008. PMID: 18308561 Clinical Trial.

5

The efficacy and toxicity of EGFR in the settings of radiotherapy: Focus on published clinical trials.

Magné N, Chargari C, Castadot P, Ghalibafian M, Soria JC, Haie-Meder C, Bourhis J, Deutsch E. Magné N, et al. Among authors: soria jc. Eur J Cancer. 2008 Oct;44(15):2133-43. doi: 10.1016/j.ejca.2008.06.029. Epub 2008 Aug 7. Eur J Cancer. 2008. PMID: 18692389 Review.

6

Acute left ventricular dysfunction induced by a panHER and VEGFR tyrosine kinase inhibitor in a phase I trial.

Bahleda R, Massard C, Soria JC, Izzedine H, Cohen A, Ederhy S. Bahleda R, et al. Among authors: soria jc. Invest New Drugs. 2010 Jun;28(3):350-2. doi: 10.1007/s10637-009-9252-6. Epub 2009 Apr 25. Invest New Drugs. 2010. PMID: 19396400

7

Phase 1 dose-escalation study of oral tyrosine kinase inhibitor masitinib in advanced and/or metastatic solid cancers.

Soria JC, Massard C, Magné N, Bader T, Mansfield CD, Blay JY, Bui BN, Moussy A, Hermine O, Armand JP. Soria JC, et al. Eur J Cancer. 2009 Sep;45(13):2333-41. doi: 10.1016/j.ejca.2009.05.010. Epub 2009 Jun 21. Eur J Cancer. 2009. PMID: 19541476 Clinical Trial.

8

Phase 0 clinical trials in oncology: an exploratory methodology for constructing a study with patients undergoing surgery for metastatic disease.

Pocard M, Soria JC, Aldaz-Carroll L, Bellet D. Pocard M, et al. Among authors: soria jc. J Clin Oncol. 2010 Oct 20;28(30):4551-3. doi: 10.1200/JCO.2010.29.2870. Epub 2010 Sep 13. J Clin Oncol. 2010. PMID: 20837954 No abstract available.

9

Phase I trials of molecularly targeted agents: should we pay more attention to late toxicities?

Postel-Vinay S, Gomez-Roca C, Molife LR, Anghan B, Levy A, Judson I, De Bono J, Soria JC, Kaye S, Paoletti X. Postel-Vinay S, et al. Among authors: soria jc. J Clin Oncol. 2011 May 1;29(13):1728-35. doi: 10.1200/JCO.2010.31.9236. Epub 2011 Mar 28. J Clin Oncol. 2011. PMID: 21444876

10

Natural history, management and pharmacokinetics of everolimus-induced-oral ulcers: insights into compliance issues.

Ferté C, Paci A, Zizi M, Gonzales DB, Goubar A, Gomez-Roca C, Massard C, Sahmoud T, André F, Soria JC. Ferté C, et al. Among authors: soria jc. Eur J Cancer. 2011 Oct;47(15):2249-55. doi: 10.1016/j.ejca.2011.03.017. Epub 2011 Apr 12. Eur J Cancer. 2011. PMID: 21489779 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

736 results

Search Page

Filters